The Impact of Impurity Analysis on Future Regulations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Impact of Impurity Analysis on Future Regulations
As technology for impurity analysis improves, scientists are gaining better information and asking for more regulatory guidance.

Pharmaceutical Technology

Others point out that the original TTC design purposefully excluded consideration of the impact of the human body's natural DNA repair system, and the fact that the underpinning scientific studies were conducted in rodents, which have DNA repair systems that are about 10-fold less effective than those in humans. "There is an approximate two to three orders of magnitude of extra conservatism built into the original TTC limit that for some reason didn't seem to get much attention in translating the concept to pharmaceutical usage," another industry scientist points out.

Meanwhile, the industry is waiting for the release of an FDA draft guidance on genotoxic impurities, which should clarify the issue.

"Right now (the draft guidance) is going through some internal editing and clearing through various levels of CDER. It is still in draft form and hopefully in the not too distant future we will get it out for comment," said Tim McGovern, supervisory pharmacologist, Division of Pulmonary and Allergy products at FDA.

In preparing to issue its own draft guidance, FDA experts have studied both the EMEA and PhRMA proposal for limits on genotoxic impurities. "We've taken a look at both of those. In various meetings where we've presented on the issue, we've said that 1.5 μg/day appears to be a good threshold limit. We also thought that a staged approach, especially during clinical development, was a reasonable approach to take. So our plan right now is to incorporate a staged TTC approach into the document," says McGovern.

"We've dealt with issues regarding genotoxic impurities for a number of years. It got to a point where the issue was coming up on a regular-enough basis that we thought a guidance document would be helpful," says McGovern. "We would have developed a guidance regardless of whether EMEA had or not."

Scientists continue to challenge both the EMEA and PhRMA TTC proposals and raise concerns that they may add significant burden on the development of virtually all small-molecule projects in the pharmaceutical industry.

Figure 2: Structural alerts. Substances containing these structures should be tested for genotoxic or carcinogenic potential.
"Any compound that has structural alerts needs to be tested by an Ames test," says Modi. Structural alerts are functional groups associated with genotoxic or carcinogenic potential" says Modi. Based on reports, 20–25% of all intermediates can be expected to test Ames positive (see Figure 2) (5, 6). These intermediates are traditionally used in "standard" chemical reactions in the synthesis of new drug substances.

"Considering the fact that only 10% of compounds are successful in reaching the market, this means 90% of the efforts will not produce anything meaningful for patients," says Modi.

IPEC is also concerned that the EMEA limits will eventually apply to excipients. Although the document states the focus is specifically on APIs, there has been some discussion about its future extension into excipients.

"We know many people in the industry have heard comments from European regulators in different venues where they have said that their intention is to apply it to excipients," says Schoneker. "This could be a big problem because the levels (the EMEA) are discussing can be exceeded easily."

IPEC plans to address genotoxic impurities in its composition guideline. It also intends to write a position paper describing its concern about the possibility of having the EMEA limits for genotoxic impurities applied to excipients. In addition to other difficulties, this application could create conflicts in international regulation: "In our discussions with FDA, they have clearly said they have no intention of applying this to excipients," says Schoneker.

"There is a lot of common ground (among) the various approaches. We'll eventually get to a point where we'll at least be in a place where everybody is comfortable, (although) they may not agree to all the details," says McGovern.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here